Monday - December 19, 2016

Bayer nominates Naomi House and Jacksplace as official race charity

Entries open on Christmas Eve for 2017 Bayer Newbury 10k


Newbury, 19 December, 2016: Race entries for the 2017 Bayer Newbury 10k are opening on Christmas Eve, Bayer has announced.  The Christmas opening date, gives runners a chance to plan the year ahead, and lace up their trainers for a few early training runs over the festive period.


This year will be a particularly notable one as the race celebrates its 10th running and the joint organisers, Bayer and Newbury AC, will be encouraging as many runners as possible to take part, to make it a special year and to help raise thousands of pounds for charity. The 2017 race will take place on Sunday, May 28.


With the opening of entries also comes the announcement that Naomi House and Jacksplace, the organisation which supports children and young people with life-limiting conditions, will once again be the nominated charity, along with Newbury AC.


The 2016 Bayer Newbury 10k raised £13,820 from entries, and in 2017 the proceeds from entries to both the 10k and the supporting junior races, will once again be divided equally between the two organisations.  However runners who want to raise money for a good cause, are also free to raise money for charities of their own choice. 


Bayer’s head of Corporate Communications, Simon Greenstreet, said: “The 2017 race is being put together as we speak, so it’s very exciting to see it taking shape already.  Bayer is very proud to be celebrating the 10th anniversary of the race, so it would be great to hear from runners who have perhaps run all nine races so far!”


Race director, Becky Elsmere, added: “From past experience we know that people do enjoy sitting down over the festive period to plan their goals and set new challenges for the year ahead. Submitting an early entry is a great way of motivating yourself to go out running and shift those extra pounds if you’ve had a few too many mince pies over Christmas!”


Naomi House and Jacksplace fundraising manager, Clare Lay, said: “We are thrilled to have been chosen again as the beneficiary charity for funds raised from the Bayer 10K.  The ongoing support we have received from Bayer over the years really does impact our children, young people and their families – we could not run our services without such help.  We are very much looking forward to supporting this event and working with Bayer in 2017”.


People wishing to enter the race can do so by going to the Bayer website or to where there will be links to the official race entry form on Christmas Eve.


Notes to editors:

Bayer: Science For A Better Life


Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to



Bayer media team: 01635 563000

Sara Bartlett: 07787 571020


Bayer’s offices in the UK and Ireland are located in Newbury (head office), Cambridge and Dublin. For more information, go to

Follow us on Twitter at:

Follow us on YouTube at:




Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.